Health Condition 1: H109- Unspecified conjunctivitis
Conditions
Interventions
Intervention1: Topical Olopatadine: 0.2% eye drop will be given once daily for 4 weeks
Control Intervention1: Topical Alcaftadine: 0.25% eye drop will be given once daily for 4 weeks
Sponsors
Neeraj Rajdan
Eligibility
Inclusion criteria
Inclusion criteria: Patient aged 5-20 years of age with history of allergic conjunctivitis presenting to OPD will be enrolled
Exclusion criteria
Exclusion criteria: Subjects undergone any ocular surgical intervention within three months Patients on steroid therapy, immunotherapeutic agents Patients using other topical eye drops (ocular lubricants) Patients used any investigational medication within one month of the study Patients with known hypersensitivity to Olopatadine & Alcaftadine Pregnant and lactating women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction in total severity score at subsequent visit will be taken as primary outcome of drug. Efficacy will be measured as mean difference between severity score at two different visits for all patients in both treatment groupsTimepoint: first day, 2nd week, 4th week | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety will be assessed by adverse events throughout the study. Adverse drug reaction (ADR) will be noted and will be assessed as per WHO UMC Causality assessment scale and Modified Hartwig Siegel’s severity scaleTimepoint: first day, 2nd week, 4th week | — |
Countries
India
Contacts
Public ContactBhavana Srivastava
Government Medical College,Haldwani
Outcome results
None listed